Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report

Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report

Based on the results of a multicenter phase II study of patients with previously treated thymic carcinoma, lenvatinib administration for unresectable thymic cancer has been covered under insurance in Japan since 2021. However, patients with interstitial lung disease (ILD) were excluded from that stu...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuki Hatakeyama, Jun Sakakibara-Konishi, Masato Tarumi, Kosuke Tsuji, Hirofumi Takahashi, Megumi Furuta, Yuta Takashima, Hidenori Kitai, Tetsuaki Shoji, Yasuyuki Ikezawa, Satoshi Konno
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Thymic cancer
Lenvatinib
Interstitial lung disease
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007125000176
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items